HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines

Executive Summary

Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.

You may also be interested in...



Church & Dwight’s Consumer Health Product Sales Spared From Pandemic Plummet In Q2

C&D said sales of its brands including vitafusion, L’il Critters and PB8 supplements, Arm & Hammer, Aim and Close-Up toothpastes and Waterpick and Spinbrush power toothbrushes helped drive 8.8% growth to $386.4m for the personal and health care categories.

Sanofi Names Estée Lauder Exec As Global Consumer Healthcare Head

President of Estée Lauder's Origins business Julie Van Ongevalle will take the reins of Sanofi's global Consumer Healthcare business from September. The French firm is banking on Van Ongevalle's digital and brand-building experience to take the business to the next level.

Sanofi Benefits From Stockpiling In Q1, Predicts Long-Term Uplift In Supplements Demand

Sanofi benefits from coronavirus-triggered stockpiling in Q1, with Consumer Healthcare head Alan Main suggesting the pandemic may have turned more consumers into regular dietary supplement users

Related Content

Topics

UsernamePublicRestriction

Register

LL1131561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel